Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C news

Show

From To
Addaction publishes major new poll on World Hepatitis Day: 4 in 5 British adults say NHS wrong to restrict access to treatment

Today, as Addaction host a large conference at The British Medical Association in London for World Hepatitis Day, the charity calls for an urgent review of the decision to ration clinically proven treatments to just 10,000 people with the virus per year, limiting access to new drugs that can effectively treat nine out of every ten carriers of the virus.

Published
20 hours ago
From
Addaction
Hepatitis C will be eradicated from Australia in a decade, doctors say

Doctors are predicting the eradication of hepatitis C from Australia by 2026 after a dramatic take-up of new-generation "revolutionary" drugs. Nearly 22,500 patients have commenced treatment since the drugs were listed on the Pharmaceutical Benefits Scheme in March, representing about 10 per cent of all people who are estimated to be living with hepatitis C.

Published
28 July 2016
From
Sydney Morning Herald
NHS England tried to sabotage hepatitis C drugs release because it couldn't afford them, doctors claim

NHS England tried to sabotage the release of hepatitis C drugs because it couldn't afford them, it has been claimed. Under current procedures, drugs approved by Nice typically become widely available to NHS patients after a statutory period of 90 days. However, the BMJ claims: “In an apparent panic over high prices and affordability, NHS England deployed many delaying tactics to block timely access to the hepatitis C drugs.”

Published
28 July 2016
From
The Independent
CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX® for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A)

AbbVie announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted a positive opinion for the use of 12 weeks of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) with ribavirin (RBV) in genotype 4 (GT4) chronic hepatitis C virus (HCV) infected adult patients with compensated cirrhosis (Child-Pugh A). VIEKIRAX with RBV is currently approved in the European Union for GT4 patients with compensated cirrhosis for 24 weeks.

Published
26 July 2016
From
AbbVie press release
WHO Updates Patent Status Info For New Hepatitis C Medicines

The World Health Organization has issued updated information on the patent status of hepatitis C medicines, including assessments of hurdles for affordable generic versions of latest drugs.

Published
21 July 2016
From
Intellectual Property Watch
'World has ignored hepatitis at its peril,' warns UN health agency ahead of World Day

With some 400 million people around the world infected with hepatitis B or C, the United Nations health agency today encouraged countries to boost testing and access to services and medicines for people in need.

Published
21 July 2016
From
UN News Centre
Fast Advance in Hepatitis C Care Prompts EMA to Revise Clinical Trial Guideline

EMA has proposed changes to its guideline on clinical trials of direct acting antiviral hepatitis C drugs. The revisions are intended to ensure the guideline reflects the dramatic changes that have happened in the hepatitis C sector since Gilead introduced its blockbuster Sovaldi (sofosbuvir).

Published
17 July 2016
From
Regulatory Affairs Professionals Society
Treatment Action Group: Pipeline Report 2016

Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.

Published
15 July 2016
From
Treatment Action Group
European Commission Grants Marketing Authorization for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C

The combination of sofosbuvir and velpatasvir (SOF/VEL) for 12 weeks was authorized for use in patients without cirrhosis or with compensated cirrhosis (Child-Pugh A), and in combination with ribavirin (RBV) for patients with decompensated cirrhosis (Child-Pugh B or C). SOF/VEL is also the first single tablet regimen approved for the treatment of patients with HCV genotype 2 and 3, without the need for RBV. Physicians also have the flexibility to consider the addition of RBV for genotype 3 infected patients with compensated cirrhosis.

Published
08 July 2016
From
Gilead press release
FDA places RG-101 for HCV on clinical hold

The FDA has verbally notified Regulus Therapeutics that its investigational new drug RG-101 for the treatment of chronic hepatitis C virus infection has been placed on clinical hold after a second patient reported a serious adverse event, according to a news release.

Published
05 July 2016
From
Healio
← First12345...115Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close